The global Cancer Biomarker market size is expected to be worth around US$ 43.7 billion by 2030, according to a new report by Vision Research Reports.
The global Cancer Biomarker market size was valued at US$ 20.3 billion in 2020 and is anticipated to grow at a CAGR of 24.3% during forecast period 2021 to 2030.
Growing prevalence of malignancies coupled with increasing focus on development of targeted therapies is a major factor affirming the positive growth of this market.
Cancer is reported to be the second leading cause of mortality in the U.S. after cardiovascular disorders. Prevalence of breast, prostate, and lung malignancies has increased at a very steep rate with an estimated number of over 1,600 people being affected in the U.S. every year. In 2017, around 200,000 cases of breast cancer have been reported in the U.S.
Increasing awareness amongst patients and healthcare professionals about the importance of early diagnosis of malignancies and rising demand for is anticipated to provide this cancer biomarker market with high growth opportunities in the coming decade. Diagnostic biomarkers for early diagnosis enable doctors on deciding better treatment alternatives leading to successful recovery in lesser time.
In addition, increasing regulatory approval of novel drugs and diagnostics pertaining to cancer biomarkers is estimated to increase the adoption rate. For instance, in 2016, Epigenomics AG, a company involved in the development of a novel epigenetic biomarker test announced that its Epi proColon was included by the Chinese government for colorectal cancer (CRC) screening.
Based on type, the market is categorized into breast, prostate, colorectal, cervical, liver, and lung. Breast cancer was the largest segment in 2020. Breast, lung, and prostate cancer cumulatively held the revenue share of over 40% in 2020. Increasing awareness about early testing and growing base of target population are the key factors contributing toward dominance
On the other hand, lung cancer is expected to witness the fastest growth over the forecast period. Growing number of diagnostic tests targeting EGFR and BRAF mutations, which act as an essential biomarker for diagnosis of non-small cell lung cancer are anticipated to accentuate the segment growth.
Based on the biomolecule, the market is further segmented into genetic, epigenetic, metabolic, and proteomic biomarkers. Genetic biomarkers owing to their extensive usage, high-reliability rate, and easier analysis held a significant market share. Over 85% of malignancies are reported to be detected with the help of genetic and proteomic biomarkers.
Epigenetics has gained high acceptance in the field of cancer diagnostics. High amount of research is being undertaken by many players for the analysis of key epigenetic modification related to cancer for further development of biomarkers targeting drugs. Increasing collaboration between and pharmaceutical companies for the development of novel drugs targeting epigenetic biomarkers is estimated to boost the growth of this segment.
Cancer biomolecules find application in various fields such as drug discovery and development, diagnostics, and personalized medicine. Diagnostics were the key revenue-generating application of the market pertaining to factors such as increasing development of biomarker-based oncology tests with high specificity and sensitivity.
Personalized medicine owing to its increasing demand and rising awareness amongst healthcare professionals is anticipated to witness flourishing growth rate. Moreover, growing approval for companion diagnostic tests for cancer drugs is expected to affirm market growth.
North America dominated the regional segment followed closely by Europe. High adoption of innovative technology, presence of key pharmaceutical companies, established R&D infrastructure pertaining to the development of novel diagnostic products and increased demand for specific & early diagnostics are the major factors for the aforementioned dominance.
However, the Asia Pacific region owing to increasing prevalence of cancer, beneficial environment for clinical trials, and increasing government funding for supporting drug development programs is anticipated to witness lucrative CAGR over the forecast period. Moreover, growing focus of pharmaceutical companies over this region coupled with rising awareness for biomarker-based diagnosis is one of the high impact-rendering drivers for growth.
Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson
Drug discovery and Development
The Cancer Biomarker market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Cancer Biomarker market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Cancer Biomarker market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Biomarker market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Cancer Biomarker market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Cancer Biomarker capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Cancer Biomarker by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Cancer Biomarker market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Cancer Biomarker market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Cancer Biomarker market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Cancer Biomarker industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Cancer Biomarker market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Cancer Biomarker market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Cancer Biomarker market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Cancer Biomarker market. These factors have benefited the growth of the global market for Cancer Biomarker. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Cancer Biomarker. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Cancer Biomarker are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are: